Skip to main content
. 2020 Oct 14;15(10):e0240517. doi: 10.1371/journal.pone.0240517

Fig 2. Effect of PT1 treatment on cell morphology.

Fig 2

Mitochondrial-deficient patient fibroblasts were treated with the AMPK agonist PT1 or DMSO (vehicle) and morphology was visualized by phase contrast microscopy. Cell lines are from patients with a defect in (A) SURF1, (B) COX10, (C) CI, and (D) POLG.